Document is current
Any future updates will be listed below
-
Authors
Pape, Marieke
Vissers, Pauline A. J.
Kato, Ken
Haj Mohammad, Nadia
Klarenbeek, Bastiaan
van Laarhoven, Hanneke W. M.
Matsuda, Tomohiro
Verhoeven, Rob H. A.
- License Information
-
More Information
Article History
Received: 22 May 2023
Accepted: 3 July 2023
First Online: 24 July 2023
Declarations
:
: HvL reports grants or advisory/speaker role from: Astellas, BMS, Daiichy, Dragonfly, Lilly, Merck, Novartis, Nordic Pharma, Servier; research funding or medical supply from: Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Philips, Roche, Servier; and has received unrestricted research funding (non-commercial) from Dutch Cancer Society, NWO/ZonMw, European Research Council, MaagLeverDarm Stichting. RV has served as a consultant for Daiichi Sankyo and reports a grant from BMS. Ken Kato has received research funds from Ono Pharmaceuticals, Bristol Myers Squibb, MSD, Merck Biopharma, Taiho Pharmaceutical, Bayer, AstraZeneca, Janssen, and Oncolys Biopharma; and honoraria from Ono Pharmaceuticals, Bristol Myers Squibb, MSD, and Taiho Pharmaceutical. NHM reports grants or advisory/speaker from BMS, Merck, Lilly, Servier and Astra Zeneca. MP, PV and BK have no disclosures to declare.
: According to the Central Committee on Research involving Human Subjects, this type of study does not require approval from an ethics committee. The study was approved by the Privacy Review Board of the NCR and the scientific committee of the Dutch Upper GI Cancer Group.
